Amendments to the Claims:

Claim 1. (original) An oral dosage form comprising oxcarbazepine adapted to be administered once a day.

Claim 2. (original) The oral dosage form comprising oxcarbazepine according to claim 1 which, when administered once a day, is released to produce constant MHD plasma levels over 24 hours.

Claim 3. (currently amended) The oral dosage form according to claim 1 ~~or 2~~ consisting of a tablet core and a coating wherein the core comprises oxcarbazepine, optionally, a filler, and at least one further excipient selected from the group comprising cellulose ethers, carboxyvinyl polymer of acrylic acid cross linked with alkyl ethers of sucrose, ~~or~~ carboxyvinyl polymer of acrylic acid cross linked with alkyl ethers of pentaerythritol and polymethacrylates.

Claim 4. (currently amended) The oral dosage form according to claim 3 wherein ~~a~~ said cellulose ether is ~~employed which is~~ hydroxypropyl methyl cellulose.

Claim 5. (original) The oral dosage form according to claim 4 wherein the weight ratio of total hydroxypropyl-methyl cellulose to oxcarbazepine is from about 1:10 to about 1:20.

Claim 6. (currently amended) The oral dosage form according to claim 3 wherein ~~a~~ said cellulose ether is ~~employed which is~~ ethyl cellulose.

Claim 7. (original) The oral dosage form according to claim 6 wherein the weight ratio of total ethyl cellulose to oxcarbazepine is from about 1:10 to about 1:20.

Claim 8. (original) The oral dosage form according to claim 3 comprising a polymethacrylate which is trimethylammonium methacrylate.

Claim 9. (currently amended) The oral dosage form according to ~~any one of~~ claims 3 ~~to 8~~ wherein said ~~comprising as a~~ filler is microcrystalline cellulose.

Claim 10. (currently amended) The oral dosage form according to ~~any one of~~ claims 1 ~~to 9~~ wherein said dosage form has an ~~having a~~ 80% or greater release of the oxcarbazepine dose within 1 hour indicated in standard in vitro dissolution tests at 37 degrees Celsius in water using sodium dodecyl sulphate as a solubilizing agent at a concentration of 1% for a 600 mg dosage form.

Claim 11. (currently amended) The oral dosage form according to ~~any one of~~ claim~~s~~ 1 ~~to 10~~ wherein said dosage form releases ~~releasing~~ oxcarbazepine at a constant release rate for 4 hours or more as indicated in standard in vitro dissolution tests at 37 degrees Celsius in water using sodium dodecyl sulphate as a solubilizing agent at a concentration of 1% for a 600 mg dosage form.

Claim 12. (original) The oral dosage form according to claim 11 wherein said dosage form releases ~~releasing~~ about 80 % of oxcarbazepine within 8 hours.

Claim 13. (original) An oral dosage form comprising oxcarbazepine which, when administered once a day, is released to produce constant MHD plasma levels over 24 hours.

Claim 14. (canceled)

Claim 15. (canceled)

Claim 16. (currently amended) A method ~~of orally administering oxcarbazepine, e.g.,~~ for the treatment of epilepsy~~, said method~~ comprising orally administering to a patient in need of oxcarbazepine ~~therapy once a day~~ an oral dosage form of ~~any one of~~ claim~~s~~ 1 ~~to 13~~.

Claim 17. (currently amended) A method of reducing the variability of bioavailability ~~levels~~ of cyclosporin A for patients during oxcarbazepine therapy, said method comprising orally administering to a patient in need of oxcarbazepine therapy an oral dosage form of ~~any one of~~ claim~~s~~ 1 ~~to 13~~.